Safety Study of Cenderitide in Stable Chronic Heart Failure
Status:
Completed
Trial end date:
2015-04-02
Target enrollment:
Participant gender:
Summary
Planned enrollment is approximately twelve subjects with stable chronic heart failure.
Enrolled subjects will receive up to eight sequential days of continuous, stepwise, dose
increasing, subcutaneous (SQ) infusions of open-label cenderitide via the Insulet Drug
Delivery System. Planned infusion rates of cenderitide will be administered to subjects
continuously during four, 48-hour infusion periods.